PMID- 33050869
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 2212-3989 (Electronic)
IS  - 1871-5265 (Linking)
VI  - 21
IP  - 5
DP  - 2021
TI  - COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail.
PG  - e270421186842
LID - 10.2174/1871526520666201013160803 [doi]
AB  - The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 
      lives globally. Disease severity and mortality rates are higher in patients with 
      underlying diabetes mellitus. Till date, there exists no effective vaccine or 
      therapy against COVID-19. However, with limited clinical data, HCQ is being used 
      for treatment and prophylaxis in patients with COVID-19. HCQ is also used as an 
      anti-diabetic drug and has been approved in India as an adjunct to diet and 
      exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus 
      (T2DM) on metformin and sulfonylurea combination in Type 2 Diabetes Mellitus 
      (T2DM). Thus, although indiscriminate use of HCQ is fraught with danger, HCQ can 
      be considered as a third-line add on anti-diabetic agent in people with T2DM amid 
      the ongoing pandemic after having ruled out the contraindications to the use of 
      this drug.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Pal, Rimesh
AU  - Pal R
AD  - Department of Endocrinology, Post Graduate Institute of Medical Education and 
      Research, Chandigarh, 160012, India.
FAU - Bhasin, Manoj K
AU  - Bhasin MK
AD  - Department of Biomedical Informatics, Emory School of Medicine, Atlanta, 
      GA-30322, United States.
FAU - Bhadada, Sanjay K
AU  - Bhadada SK
AD  - Department of Endocrinology, Post Graduate Institute of Medical Education and 
      Research, Chandigarh, 160012, India.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Infect Disord Drug Targets
JT  - Infectious disorders drug targets
JID - 101269158
SB  - IM
MH  - *COVID-19
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Humans
MH  - India
MH  - Pandemics
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19
OT  - HCQ
OT  - SARS-CoV-2.
OT  - T2DM
OT  - diabetes mellitus
OT  - pandemic
OT  - vaccine
EDAT- 2020/10/15 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/10/14 08:54
PHST- 2020/05/16 00:00 [received]
PHST- 2020/08/09 00:00 [revised]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2020/10/14 08:54 [entrez]
AID - IDDT-EPUB-110647 [pii]
AID - 10.2174/1871526520666201013160803 [doi]
PST - ppublish
SO  - Infect Disord Drug Targets. 2021;21(5):e270421186842. doi: 
      10.2174/1871526520666201013160803.